6 completed. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Completed 6 |
Follow Stalevo: new trials by email Literature Review of Stalevo trials Research Report on Stalevo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetic Study in Healthy Volunteers levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 15 | 2015-08-01 | 2016-01-14 |
| Levodopa Concentration Profile With Stalevo 75/125 mg Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa) - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2009-12-01 | 2010-08-13 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-07-01 | 2007-06-22 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-06-01 | 2007-06-22 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-06-01 | 2007-06-22 |
| Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers ELC200 (carbidopa+levodopa+entacapone) - Healthy | Phase 1 | Completed | Novartis | 42 | 2006-05-01 | 2007-06-22 |
Parkinson Disease (2) · Fasting (1)
Novartis (4) · Orion Corporation, Orion Pharma (2)
Germany (4) · Finland (2)
Kimmo Ingman (1) · Mika Scheinin, MD (1)